Merci au Dr @nvillain-alz.bsky.social pour sa présentation sur les nouveaux traitements par immunothérapie #alzheimer #traitements.

🎉 We’re now on BlueSky! Follow the European Journal of Neurology 👉 @europeanjournalofneurology.ean.org Stay up-to-date with the latest in #Neurology! #MedSky #NeuroSky

Part 1 focused on patient selection challenges. Part 2 will focus on health system readiness. Tara Carlisle and myself were co-first authors on these and benefited greatly from our senior author, Kirk Daffner.

The American Neuropsychiatric Association (No bsky, yet..) dementia special interest group, which I've been the leader of for a number of years, has been working on a two part series for the Journal of Neuropsychiatry and Clinical Neuroscience. Part 1 here. www.psychiatryonline.org/doi/10.1176/...

"We call on researchers worldwide to unite and join us ... If you love freedom, come and help us stay free," French President Emmanuel Macron said at Paris' Sorbonne University #BrainDrain www.reuters.com/science/eus-...

RV le 2 juin pour les #EntretiensAlzheimer : avancées de la recherche, nouveaux traitements, prédiction de la maladie… avec @nvillain-alz.bsky.social et #AudreyGabelle Gratuit sur inscription 👉 entretiensalzheimer.org/index.php/il...

Scientists must push back against the threat of rising white nationalism and the dangerous and pseudoscientific ideas of eugenics https://go.nature.com/42Zryw1

🧠 PhD position available! Study polypathology in the medial temporal lobe at the Paris Brain Institute with @lemwisse.bsky.social , @nvillain-alz.bsky.social and myself. This exciting project combines neuroimaging, neuropathology and cognition! Please share widely 🙏

Exciting opportunity for a PhD position at the @institutducerveau.bsky.social on a European collaborative project under the supervision of medial temporal lobe specialists! Spread the word! bsky.app/profile/lemw...

am pleased to share our letter, highlighting that the science does not yet support regulatory approval of amyloid-targeting therapies for AD based solely on biomarker evidence. alz-journals.onlinelibrary.wiley.com/doi/full/10....

💊Les médicaments contre l’anxiété, c’est pour une courte durée. Ceux contre l’insomnie, c’est pour quelques nuits ! ↪️Découvrez notre campagne pour favoriser le #BonUsage des médicaments contre l’anxiété et l’insomnie sévères👉http://lesmedicamentsetmoi.fr #MedicamentsEtMoi #GCN2025

Great news today. Lecanemab approved in Europe. I quibble with the fact that genetic discrimination is permitted, but this probably won’t last long.

1/ 🚨 The @ec.europa.eu must now take a stance on lecanemab. After months of delays and an inconclusive Appeal Committee outcome, patients with early Alzheimer’s disease are left in limbo. This has real-world consequences. 🧠🕰️ www.alzheimer-europe.org/news/after-a...

Just out in JAMA Neurol blood biomarkers are powerful—but without cognitive phenotyping, we risk more noise than signal. Plasma p-tau217 needs clinical context or we’ll end up in a false-positive factory! Clinico-biological AD is a reality! 👉🏻 jamanetwork.com/journals/jam... bsky.app/profile/vinc...

Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...

#VendrediLecture 📚 Un extrême centre s'accrochant au pouvoir sans majorité et faisant alliance avec l’extrême-droite : cette histoire se déroule en Allemagne entre 1930 et 1933. 👉 Avec "Les irresponsables", Johann Chapoutot analyse les conditions de l'arrivée d'Hitler au pouvoir : swll.to/1K1bU8R

Recent research published in Alzheimer’s and Dementia investigates plasma phosphorylated tau (p-tau) levels in a diverse cohort. Results demonstrate differences in plasma p-tau in Black/African American and non-White Hispanic participants. alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Results from our AntiRetroviral Therapy for Alzheimer's Disease (ART-AD) clinical trial are available online today and will be included in the inaugural issue of npj Dementia. rdcu.be/edfwq

Ten years ago if you had written a dystopian SF story in which the person in charge of U.S. public health did a press event at a fast food joint to say that fried food is good but measles vaccines cause measles the ghost of Philip K. Dick would have said that you were being too bleak and unrealistic

Just donated. In Euros. F*ck America. 🇺🇦

Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Struggling to compare treatment effects across different cognitive measures? Check out our new paper. alz-journals.onlinelibrary.wiley.com/doi/full/10....

1/ NEW: Lecanemab in France The French Federation of Memory Clinics just released its appropriate use recommendations for #Lecanemab in early #Alzheimers. What’s new? How does it compare to U.S. guidelines? A thread 🧵⬇️ www.sciencedirect.com/science/arti...

🧠🔬The Scientific Program for Day 3 of the Buenos Aires Hub is here! Location: Amigos del Bellas Artes, Buenos Aires, Argentina #NeuroscienceNext #BuenosAiresHub #neuroscience #alzheimersAssociation #argentina #fleni #alzheimer #neurociencia #neuropsicologia

Dr. @nvillain-alz.bsky.social (@sorbonne-universite.fr), plenary speaker at the #AAICNeuro POA hub, delivered a fantastic talk titled "The Great Debate in Diagnosing Alzheimer’s Disease: More Than Just a β Test." Thank you for sharing your insights with us, Dr. Villain! 👏@alzassociation.bsky.social

4 days to go for AAIC Neuroscience Next 2025 🎊 Don't miss the Buenos Aires Hub!

AD testing outside physician's direct care has zero pre-test probability, no clinical input or context. This will kill people. Neurogen might become another word for Theranos. firstwordhealthtech.com/story/5936237

🔥Tribune signée par nombreux acteurs de la recherche française "Les décisions prises dans les dernières semaines aux USA compromettent sérieusement ces liens scientifiques (...) La recherche scientifique est un bien commun qui transcende les frontières politiques" www.lemonde.fr/idees/articl...

It appears RFK Jr has read this dangerously misinformed book and may try to come for the “amyloid cabal.” @bostonglobe.com @statnews.com @alzassociation.bsky.social @nytopinion.nytimes.com

Paris 🇫🇷🗼 @institutducerveau.bsky.social Biomarker Group dinner with special guest! Thanks Przemek (aka Przemysław Radosław Kac) for visiting us and continuing the biomarker innovation!

BREAKING NEWS: CDC orders mass retraction and revision of submitted research across all science and medicine journals. Banned terms must be scrubbed. Goes beyond MMWR +other CDC pubs. Applies to research already submitted to top medical journals. Take a look. open.substack.com/pub/insideme...

I made some edits for people who think behavioral neurology should focus more on proteins then behavior:

🌐 Dr. @nvillain-alz.bsky.social will be part of Buenos Aires Hub 2025 to present "The great debate in diagnosing Alzheimer's disease: more than just a β test" Don't miss his presentation! Register now: 📎 bit.ly/NeuroscienceNext2025_Registration

Meet our #NeuroSpeaker Nicolas Villain, MD, PhD! He trained as an MD and a clinical fellow in Paris and he did his PhD with Dr. Gaël Chételat in Caen, where he worked on multimodal neuroimaging and disconnection mechanisms in AD #neuroscience #neuropsychology #alzheimer #dementia #test #endalz

Propagation of pathologic α-synuclein from kidney to brain may contribute to Parkinson’s disease www.nature.com/articles/s41...

White matter hyperintensities and TDP-43 pathology in Alzheimer's disease 👉AD-TDP type-α showed greater total and regional WMH burden (particularly in subcortical frontotemporal and basal ganglia regions) than TDP-43 negatives and AD-TDP type-β. alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

What an incredible time period to be working on updated appropriate use criteria for amyloid and tau PET! Awesome group to work with...I learned so much🧠 alz-journals.onlinelibrary.wiley.com/doi/10.1002/... @alzassociation.bsky.social @snm-mi.bsky.social

Here comes my first Bluesky post: Happy to share new exciting job opportunities with Alzheimer Europe - if you have experience and a background in communication, conference organisation or finance, why don't you apply for one of these three positions? www.alzheimer-europe.org/news/we-are-...

🚨Paper Alert🚨 Thrilled to share this paper published in the @agsjournal.bsky.social , on the prevalence of anticholinergic and sedative drugs used in older adults (aged 65+)💊🧠 👉data from the 🇫🇷French National Health Data System (#SNDS) 👉n=16,938,152 🚨prevalence=32.8% shorturl.at/0PsQF 🧵👇1/

Wow. A tour de force on neuroinflammation and AD! My bias is that inflammation is 100% part of the process but more likely reactionary to the problem, but it likely accelerates the disease… Excited to give this a detailed read though!

In the late 1980s, before anyone knew how Abeta was made, Wisniewski hypothesized that microglia made plaques because TEM showed amyloid in communication with microglial ER. Something to this I suppose? Maybe endosomes, not ER? I’m not a cell biologist. www.nature.com/articles/s41...

Should amyloid-lowering therapies be approved based on biomarker evidence alone? With @vincentplanche.bsky.social we argue for prioritizing clinical endpoints over unvalidated surrogates like amyloid load in AD trials. Read our full critique on AlzForum: www.alzforum.org/news/researc...

Nous avons toujours besoin de vous (et de votre temps). Merci de votre soutien!

Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪

There are many reasons why the suggestion to abandon examining our patients in behavioral neurology is a bad idea. One that is often overlooked regarding bedside cognitive screening, is that it allows the family to appreciate the level of mental functioning. #endalz pn.bmj.com/content/earl...

Given the exodus of academics from X to BlueSky, isn't it time that journal websites added a 'share to bluesky' option?

New work from our postdoc Elouise Koops just got published: #locuscoeruleus metabolism is elevated in preclinical Alzheimer’s disease, and provides resilience against cognitive decline! In collaboration with Joyita Dutta (UMass) alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Postmortem evidence that higher brain GFAP levels are associated with higher brain amyloid burden 👇👇👇👇 link.springer.com/article/10.1...

This is excellent use of multimodal imaging that is available clinically. Both Alzheimer’s disease and Lewy body disease can involve posterior regions on FDG PET but LBD by itself doesn’t cause significant MRI atrophy. See also example of an MTA co-path case too academic.oup.com/brain/advanc...